IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis
Sun, Feng1,2,3; Yu, Kai4; Wu, Shanshan1; Zhang, Yuan1; Yang, Zhirong1; Shi, Luwen2; Ji, Linong5; Zhan, Siyan1
关键词Glucagon-like Peptide-1 Receptor Agonists Cardiovascular Safety Efficacy Network Meta-analysis Type 2 Diabetes Mellitus
刊名DIABETES RESEARCH AND CLINICAL PRACTICE
2012-12-01
DOI10.1016/j.diabres.2012.09.004
98期:3页:386-395
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]RANDOMIZED CLINICAL-TRIALS ; MYOCARDIAL-INFARCTION ; ANTIDIABETIC AGENTS ; EXENATIDE TWICE ; PARALLEL-GROUP ; LIRAGLUTIDE ; THERAPIES ; INSULIN ; EFFICACY ; DISEASE
英文摘要

Aims: Integrating evidence from all randomized controlled trials (RCTs) of glucagon-like peptide-1 receptor agonists (GLP-1s) to assess the safety of cardiovascular disease (CVD) and efficacy of glycemic control.

Methods: Besides performing pairwise meta-analysis, network meta-analysis of all RCTs was used to combine direct and indirect estimates of the effect of GLP-1 with placebo, active comparator drugs (ACD), or another GLP-1 agent with treatment duration >8 weeks in T2DM patients, 15,883 for CVD safety from 45 RCTs and 14,136 for glycemic control from 36 RCTs.

Results: For CVD safety, both of the results from pairwise and network meta-analysis failed to demonstrate significant difference between any two comparators. For glycemic control, the effect of any GLP-1 was better than placebo, but no difference was found between GLP-1s. We also found that liraglutide was the only GLP-1 drug shown to be more effective on improving glycemic control than ACD and exenatide. The results based on direct or indirect estimates were similar for two outcomes.

Conclusion: Our network meta-analysis provides a complete picture of the associations between GLP-1s, ACD and placebo on CVD safety and glycemic control. The GLP-1s are promising candidates for the treatment of T2DM, but more long-term trials are needed to confirm potential CVD safety. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

语种英语
WOS记录号WOS:000312133700009
项目编号2010JC15 ; RCZX200923
资助机构Doctoral Fund of corps ; High level talent project of Shihezi University ; Tianjin Municipal Health Bureau of industry of key reasearch projects
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53501
专题北京大学公共卫生学院
北京大学药学院_药事管理与临床药学系
北京大学公共卫生学院_公共卫生学院
作者单位1.Tianjin Fifth Cent Hosp, Dept Orthoped, Tianjin 300450, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
3.Peking Univ, Int Res Ctr Med Adm, Beijing 100191, Peoples R China
4.Shihezi Univ, Coll Med, Dept Prevent Med, Shihezi 832002, Peoples R China
5.Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Sun, Feng,Yu, Kai,Wu, Shanshan,et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis[J]. DIABETES RESEARCH AND CLINICAL PRACTICE,2012,98(3):386-395.
APA Sun, Feng.,Yu, Kai.,Wu, Shanshan.,Zhang, Yuan.,Yang, Zhirong.,...&Zhan, Siyan.(2012).Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis.DIABETES RESEARCH AND CLINICAL PRACTICE,98(3),386-395.
MLA Sun, Feng,et al."Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis".DIABETES RESEARCH AND CLINICAL PRACTICE 98.3(2012):386-395.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Feng]的文章
[Yu, Kai]的文章
[Wu, Shanshan]的文章
百度学术
百度学术中相似的文章
[Sun, Feng]的文章
[Yu, Kai]的文章
[Wu, Shanshan]的文章
必应学术
必应学术中相似的文章
[Sun, Feng]的文章
[Yu, Kai]的文章
[Wu, Shanshan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。